Active Recombinant Human ICOSLG Protein, His-tagged
Cat.No. : | ICOSLG-1027H |
Product Overview : | Recombinant Human ICOSLG (Accession # O75144) Asp19-Ser258, fused with a C-terminal 6-His tag, was produced in Human embryonic kidney cell, HEK293-derived. |
- Specification
- Gene Information
- Related Products
Source : | HEK293 Cells |
Species : | Human |
Tag : | His |
Predicted N Terminal : | Asp19 |
Form : | Lyophilized from a 0.2 µm filtered solution in PBS. |
Bio-activity : | Measured by its ability to co-stimulate IL-4 secretion by D10.G4.1 mouse helper T cells in the presence of anti-CD3.The ED50 for this effect is typically 0.3-1.5 µg/mL.Measured by its ability to stimulate human T cell proliferation in the presence of anti-CD3. Wang, S. et al. (2000) Blood 96:2808.The ED50 for this effect is typically 0.3-1.2 µg/mL. |
Molecular Mass : | Recombinant Human ICOSLG, His-tagged has a calculated MW of 28 kDa. In SDS-PAGE migrates as 59-64 kDa, reducing conditions. |
Protein length : | Asp19-Ser258 |
Purity : | >95%, by SDS-PAGE with silver staining. |
Storage : | Avoid repeated freeze-thaw cycles. No activity loss was observed after storage at: In lyophilized state for 1 year (4ºC); After reconstitution under sterile conditions for 3 months (-70ºC). |
Gene Name : | ICOSLG inducible T-cell co-stimulator ligand [ Homo sapiens ] |
Official Symbol : | ICOSLG |
Synonyms : | ICOSLG; inducible T-cell co-stimulator ligand; ICOSL; ICOS ligand; B7 homolog 2; B7 homologue 2; B7 H2; B7 related protein 1; B7H2; B7RP 1; B7RP1; CD275; GL50; ICOS L; KIAA0653; B7-like protein Gl50; B7-related protein 1; transmembrane protein B7-H2 ICOS ligand; B7-H2; LICOS; B7RP-1; ICOS-L; |
Gene ID : | 23308 |
mRNA Refseq : | NM_015259 |
Protein Refseq : | NP_056074 |
MIM : | 605717 |
UniProt ID : | O75144 |
Chromosome Location : | 21q22.3 |
Products Types
◆ Recombinant Protein | ||
ICOSLG-598H | Recombinant Human ICOSLG Protein | +Inquiry |
ICOSLG-794H | Recombinant Human ICOSLG Protein, MYC/DDK-tagged | +Inquiry |
ICOSLG-039H | Recombinant Human ICOSLG Protein, His-tagged | +Inquiry |
ICOSLG-90H | Recombinant Human ICOSLG Protein, His (Fc)-Avi-tagged | +Inquiry |
ICOSLG-1515R | Recombinant Rhesus Monkey ICOSLG Protein, hIgG4-tagged | +Inquiry |
◆ Lysates | ||
ICOSLG-1095HCL | Recombinant Human ICOSLG cell lysate | +Inquiry |
Related Gene
For Research Use Only. Not intended for any clinical use. No products from Creative BioMart may be resold, modified for resale or used to manufacture commercial products without prior written approval from Creative BioMart.
Inquiry
- Q&As
- Reviews
Q&As (6)
Ask a questionICOSLG protein plays an important regulatory role in the immune system. It binds to ICOS receptors on the surface of T cells and promotes the activation and differentiation of T cells, which in turn affects the strength and direction of the immune response.
Certain biomolecules can serve as molecular markers of ICOSLG proteins, such as mRNAs or proteins of ICOSLG proteins detected in biological samples such as blood and urine. These markers can be used for early diagnosis of disease, prognostic judgment, or monitoring of treatment efficacy.
Factors to be considered in drug development for ICOSLG proteins include drug specificity, safety, pharmacokinetic properties, etc. In addition, the dosage form, route of administration, and dosage of the drug need to be considered to develop an effective treatment plan.
A variety of factors can affect the expression of ICOSLG protein, including cytokines, inflammatory factors, immunostimulants, etc. These factors can stimulate or inhibit the expression of ICOSLG protein, which in turn affects the strength and direction of the immune response.
Therapeutic strategies targeting ICOSLG proteins include inhibition of its activity, modulation of its expression, and gene therapy. For example, the development of small molecule inhibitors or antibody drugs against ICOSLG protein to inhibit its aberrant activity in disease, or the regulation of ICOSLG protein expression through gene knockout or overexpression technology.
Assessing the potential of ICOSLG proteins as drug targets requires a comprehensive analysis. Factors to consider include the structure and function of the ICOSLG protein, its role in the immune system, interactions with existing medications, and potential therapeutic efficacy and safety.
Customer Reviews (3)
Write a reviewICOSLG performed very well in the experiments, with reliable and reproducible results.
The stability is very strong, and it can maintain the stability of its structure and function even after a lot of use, which shows its excellent quality and reliability.
The storage conditions are simple, and it will not be denatured even at ultra-low temperatures.
Ask a Question for All ICOSLG Products
Required fields are marked with *
My Review for All ICOSLG Products
Required fields are marked with *
Inquiry Basket